Intellia Therapeutics (NTLA) Preferred Stock Liabilities (2015 - 2016)
Intellia Therapeutics (NTLA) reported Preferred Stock Liabilities of $88.6 million for Q1 2016, little changed on a QoQ basis from $88.6 million in Q4 2015.
Intellia Therapeutics (NTLA) has 2 years of Preferred Stock Liabilities data on file, last reported at $88.6 million in Q1 2016.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $88.6 million in Q1 2016, while the trailing twelve-month figure through Mar 2016 was $88.6 million (changed N/A YoY) and the FY2015 annual result came in at $88.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $88.6 million in Q1 2016 per NTLA's latest filing, from $88.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $88.6 million in Q1 2016 and bottomed at $88.6 million in Q4 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 88.62 Mn |
| Dec 31, 2015 | 88.56 Mn |